Articles

The Interview Issue: John Lechleiter

John Lechleiter, CEO of Eli Lilly and Co., said the company remained confident about its drug pipeline even after it weathered a string of failed clinical trials.

Read More

The Interview Issue: Eugene White

Eugene White, the president of Martin University, had become restless in retirement when the opportunity to lead the struggling black liberal arts college surfaced.

Read More

Applications to Marian medical school keep rising

health care paul evans marian watch videoWith the number of applications to Marian’s College of Osteopathic Medicine running twice as high as initially expected, school leaders say they are confident Marian can help reduce a looming physician shortage in Indiana.

Read More

Indiana’s least competitive places to buy health insurance

Four of the 10 metro areas that will see the biggest decrease in competition from the Anthem-Cigna merger are in Indiana, according to an analysis by the American Medical Association—with Indianapolis facing the second-biggest impact among all of Anthem’s markets nationwide.

Read More
rop-aphilbert-061713-2col.jpg

Steve Hilbert seeks comeback in insurance

The controversial co-founder and former CEO of life insurance giant Conseco Inc. (now CNO Financial Group Inc.) spearheaded the purchase of a small life insurance company operated out of Texas and plans to gradually build up its operations here.

Read More

Community set to go whole hog on new value-based payments

CEO Bryan Mills has set a goal to make 75 percent of revenue—or $1.5 billion a year—be covered by value-based contracts—which means Community would be rewarded for keeping patients out of the hospital. A new venture is Mills’ strategy to get there.

Read More

Obamacare, HIP 2.0 goosing hospital profits—for now

More paying customers helped Community Health Network pull in $47 million in second-quarter profits, a story being repeated at not-for-profit hospitals around the country as Obamacare has boosted the number of insured customers to unprecedented highs.

Read More

Novo Nordisk buying 2 DiMarchi-launched drug firms

Calibrium LLC and MB2 LLC, both based in Carmel, have agreed to be sold for undisclosed amounts. They were developing diabetes drugs discovered by the research team of Richard DiMarchi, a chemistry professor at Indiana University.

Read More